OSI Joins Genentech In Eye Disease Market With $935 Mil. Eyetech Purchase

OSI Pharmaceuticals' existing partnership with Genentech will be unaffected by the firm's acquisition of Eyetech Pharmaceuticals, CEO Colin Goddard assured investors Aug. 22